von Hardenberg J, Büsing K-A, Nuhn P, Ritter M
Klinik für Urologie, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
Institut für Klinische Radiologie und Nuklearmedizin der Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Deutschland.
Urologe A. 2017 Nov;56(11):1410-1416. doi: 10.1007/s00120-017-0513-2.
Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resistant prostate cancer evidence for its use is not available.
在德国，用于前列腺癌定位的前列腺特异性膜抗原（PSMA）正电子发射断层扫描-计算机断层扫描（PET-CT）成像越来越普及。本文综述了其在不同疾病阶段的进展和局限性。由于PSMA PET-CT成像检测到的原发性癌症中寡转移疾病的临床相关性尚未完全明确，因此仅应在临床试验中使用。在进行了根治性治疗的复发性前列腺癌中，PSMA PET-CT在挽救性治疗规划方面显示出令人鼓舞的潜力。在转移性去势抵抗性前列腺癌中，尚无使用该技术的证据。
